CG Oncology(US:CGON)2025-05-13 12:15Financial Performance - Cash and cash equivalents and marketable securities as of March 31, 2025, were $688.4 million, down from $742.0 million as of December 31, 2024[8]. - Research and Development (R&D) expenses for Q1 2025 were $27.5 million, an increase of 60.6% compared to $17.2 million in Q1 2024[8]. - General and Administrative (G&A) expenses for Q1 2025 were $14.8 million, up from $5.8 million in Q1 2024, reflecting a 155.2% increase[8]. - Net loss for Q1 2025 was $34.5 million, or ($0.45) per share, compared to a net loss of $16.9 million, or ($0.36) per share, in Q1 2024[8]. - The company expects its existing cash and marketable securities to fund operations into the first half of 2028[8]. Clinical Trials and Research - The Phase 3 BOND-003 trial showed a 75.5% complete response rate at any time, with a 42.3% complete response rate at 24 months by Kaplan-Meier estimation[5]. - Cohort P demonstrated a promising 90.5% high-grade recurrence-free survival at 3 and 9 months in patients with BCG-unresponsive Ta/T1 disease[5]. - The CORE-008 Cohort CX trial has been initiated to evaluate the combination of cretostimogene and gemcitabine in high-risk BCG-exposed NMIBC patients[5]. Future Plans and Market Potential - The company expects to initiate its Biologics License Application (BLA) submission for cretostimogene in the second half of 2025[2]. - The company anticipates that cretostimogene could address over 70% of the market opportunity for innovative therapies in NMIBC[2].